2.23
price up icon1.83%   0.04
after-market 시간 외 거래: 2.20 -0.03 -1.35%
loading
전일 마감가:
$2.19
열려 있는:
$2.19
하루 거래량:
1.07M
Relative Volume:
0.57
시가총액:
$55.54M
수익:
-
순이익/손실:
$-51.50M
주가수익비율:
-0.5575
EPS:
-4
순현금흐름:
$-47.10M
1주 성능:
-5.91%
1개월 성능:
+54.86%
6개월 성능:
-75.08%
1년 성능:
-70.13%
1일 변동 폭
Value
$2.01
$2.23
1주일 범위
Value
$2.01
$2.325
52주 변동 폭
Value
$0.87
$12.85

아웃룩 테라퓨틱스 Stock (OTLK) Company Profile

Name
명칭
Outlook Therapeutics Inc
Name
전화
(609) 619-3990
Name
주소
111 S. WOOD AVENUE, ISELIN, NJ
Name
직원
23
Name
트위터
Name
다음 수익 날짜
2024-08-14
Name
최신 SEC 제출 서류
Name
OTLK's Discussions on Twitter

OTLK을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
OTLK
Outlook Therapeutics Inc
2.23 55.54M 0 -51.50M -47.10M -4.00
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
422.00 108.68B 10.63B -479.80M -1.35B -1.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
681.58 74.90B 13.85B 4.65B 3.32B 40.41
Biotechnology icon
ARGX
Argen X Se Adr
640.52 38.30B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
246.27 31.76B 2.09B -332.26M 16.06M -2.62
Biotechnology icon
BNTX
Biontech Se Adr
111.93 26.83B 3.30B -501.07M 1.03B -2.1146

아웃룩 테라퓨틱스 Stock (OTLK) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-12-02 다운그레이드 Chardan Capital Markets Buy → Neutral
2024-03-27 업그레이드 BTIG Research Neutral → Buy
2024-02-15 업그레이드 Chardan Capital Markets Neutral → Buy
2024-01-25 업그레이드 Guggenheim Neutral → Buy
2023-12-27 업그레이드 CapitalOne Equal Weight → Overweight
2023-08-31 다운그레이드 Chardan Capital Markets Buy → Neutral
2023-08-31 다운그레이드 H.C. Wainwright Buy → Neutral
2023-08-30 다운그레이드 BTIG Research Buy → Neutral
2023-08-30 다운그레이드 Cantor Fitzgerald Overweight → Neutral
2023-08-30 다운그레이드 CapitalOne Overweight → Equal Weight
2023-08-30 다운그레이드 Guggenheim Buy → Neutral
2023-07-13 개시 CapitalOne Overweight
2023-04-03 개시 Guggenheim Buy
2023-02-06 개시 Cantor Fitzgerald Overweight
2022-10-31 개시 BTIG Research Buy
2022-09-13 개시 Chardan Capital Markets Buy
2019-09-11 개시 Ladenburg Thalmann Buy
2019-05-16 개시 Oppenheimer Outperform
2019-04-22 개시 Ascendiant Capital Markets Buy
모두보기

아웃룩 테라퓨틱스 주식(OTLK)의 최신 뉴스

pulisher
11:44 AM

Outlook Therapeutics’ (OTLK) “Buy” Rating Reiterated at HC Wainwright - Defense World

11:44 AM
pulisher
Jan 18, 2025

Outlook Therapeutics (NASDAQ:OTLK) Earns Buy Rating from Guggenheim - MarketBeat

Jan 18, 2025
pulisher
Jan 18, 2025

Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace

Jan 18, 2025
pulisher
Jan 18, 2025

Outlook Therapeutics (NASDAQ:OTLK) Receives Buy Rating from HC Wainwright - MarketBeat

Jan 18, 2025
pulisher
Jan 18, 2025

Short Interest in Outlook Therapeutics, Inc. (NASDAQ:OTLK) Drops By 17.7% - MarketBeat

Jan 18, 2025
pulisher
Jan 17, 2025

Outlook Therapeutics' (OTLK) Buy Rating Reaffirmed at HC Wainwright - MarketBeat

Jan 17, 2025
pulisher
Jan 16, 2025

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Jan 16, 2025
pulisher
Jan 16, 2025

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug - Benzinga

Jan 16, 2025
pulisher
Jan 16, 2025

Outlook falls 10% on ONS-5010 update, warrant inducements - MSN

Jan 16, 2025
pulisher
Jan 16, 2025

Outlook Therapeutics, Inc. Announces Complete Twelve Week Efficacy and Safety Results of Northeast EIGHT Clinical Trial - Marketscreener.com

Jan 16, 2025
pulisher
Jan 16, 2025

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial - GlobeNewswire

Jan 16, 2025
pulisher
Jan 16, 2025

Outlook Therapeutics' ONS-5010 Matches Ranibizumab in 12-Week AMD Trial Results - StockTitan

Jan 16, 2025
pulisher
Jan 16, 2025

Analysts Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) Price Target at $32.73 - Defense World

Jan 16, 2025
pulisher
Jan 13, 2025

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Jan 13, 2025
pulisher
Jan 12, 2025

Outlook Therapeutics Reports 2024 Financial Results - MSN

Jan 12, 2025
pulisher
Jan 09, 2025

Barclays PLC Increases Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Jan 09, 2025
pulisher
Jan 09, 2025

Geode Capital Management LLC Raises Stake in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Jan 09, 2025
pulisher
Jan 08, 2025

OTLKOutlook Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan

Jan 08, 2025
pulisher
Jan 08, 2025

Outlook Therapeutics® Participates in Virtual Investor "What This Means” Segment - The Manila Times

Jan 08, 2025
pulisher
Jan 08, 2025

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment - GlobeNewswire

Jan 08, 2025
pulisher
Jan 08, 2025

Outlook's LYTENAVA Makes History: First Approved Ophthalmic Bevacizumab for Wet AMD in UK - StockTitan

Jan 08, 2025
pulisher
Jan 06, 2025

Spartan Delta Corp (SDE-T) QuotePress Release - The Globe and Mail

Jan 06, 2025
pulisher
Jan 06, 2025

Outlook Therapeutics (NASDAQ:OTLK) versus Candel Therapeutics (NASDAQ:CADL) Financial Survey - Defense World

Jan 06, 2025
pulisher
Jan 03, 2025

State Street Corp Buys 21,201 Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Jan 03, 2025
pulisher
Jan 02, 2025

Analysts Offer Predictions for OTLK Q1 Earnings - Defense World

Jan 02, 2025
pulisher
Jan 01, 2025

OTLK FY2026 EPS Lifted by Brookline Capital Management - Defense World

Jan 01, 2025
pulisher
Dec 30, 2024

Age-related Vision Dysfunction Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Epidemiology, Therapies, Treatment, Companies by DelveInsight - The Globe and Mail

Dec 30, 2024
pulisher
Dec 30, 2024

Biotech Alert: Searches spiking for these stocks today - TipRanks

Dec 30, 2024
pulisher
Dec 30, 2024

Outlook Therapeutics Stock Surges on Positive Outlook Despite Lo - GuruFocus.com

Dec 30, 2024
pulisher
Dec 30, 2024

Outlook Therapeutics Stock Surges on Positive Outlook Despite Loss - Yahoo Finance

Dec 30, 2024
pulisher
Dec 29, 2024

Outlook Therapeutics Faces Business Risks from Third-Party Manufacturing Dependencies - MSN

Dec 29, 2024
pulisher
Dec 28, 2024

Outlook Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - Marketscreener.com

Dec 28, 2024
pulisher
Dec 28, 2024

Outlook Therapeutics provides ONS-5010/LYTENAVA update - Yahoo Finance

Dec 28, 2024
pulisher
Dec 27, 2024

Outlook Therapeutics Inc. (OTLK) reports earnings - Quartz

Dec 27, 2024
pulisher
Dec 27, 2024

Outlook Therapeutics Shares Up, Outlines Plans for Macular Degeneration Treatment - Marketscreener.com

Dec 27, 2024
pulisher
Dec 27, 2024

Outlook Therapeutics Inc Reports Fiscal Year 2024 EPS of -$4.06, Missing Revenue Estimate of $0.24 Million - GuruFocus.com

Dec 27, 2024
pulisher
Dec 27, 2024

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update - The Manila Times

Dec 27, 2024
pulisher
Dec 27, 2024

Outlook Therapeutics Secures EU Approval for LYTENAVA™, First Bevacizumab Eye Treatment for Wet AMD - StockTitan

Dec 27, 2024
pulisher
Dec 22, 2024

Brokerages Set Outlook Therapeutics, Inc. (NASDAQ:OTLK) PT at $42.34 - Defense World

Dec 22, 2024
pulisher
Dec 21, 2024

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Outlook Therapeutic - GuruFocus.com

Dec 21, 2024
pulisher
Dec 20, 2024

Charles Schwab Investment Management Inc. Grows Stock Position in Outlook Therapeutics, Inc. (NASDAQ:OTLK) - Defense World

Dec 20, 2024
pulisher
Dec 16, 2024

Outlook Therapeutics : Reorganization Form 8 K - Marketscreener.com

Dec 16, 2024
pulisher
Dec 14, 2024

Outlook Therapeutics® Streamlines Operations - The Manila Times

Dec 14, 2024
pulisher
Dec 14, 2024

Outlook Therapeutics, Inc. Streamlines Operations - Marketscreener.com

Dec 14, 2024
pulisher
Dec 13, 2024

Outlook Therapeutics to Cut 23% of Workforce in Push for Lytenava Commercial Launch - MarketWatch

Dec 13, 2024
pulisher
Dec 09, 2024

After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright - Yahoo Finance

Dec 09, 2024
pulisher
Dec 05, 2024

Outlook nabs NICE nod in wet AMD - The Pharma Letter

Dec 05, 2024
pulisher
Dec 04, 2024

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - The Manila Times

Dec 04, 2024
pulisher
Dec 04, 2024

Outlook Therapeutics® Announces NICE Recommendation of - GlobeNewswire

Dec 04, 2024
pulisher
Dec 04, 2024

Outlook Therapeutics' LYTENAVA Secures Groundbreaking NICE Recommendation for Wet AMD Treatment | OTLKW Stock News - StockTitan

Dec 04, 2024

아웃룩 테라퓨틱스 (OTLK) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$30.75
price down icon 0.65%
$71.93
price down icon 0.75%
$19.03
price up icon 4.62%
$358.93
price down icon 2.04%
biotechnology ONC
$210.08
price up icon 2.31%
$111.93
price down icon 0.74%
자본화:     |  볼륨(24시간):